4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2000
Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German Study Group and \"Arbeitsgemeinschaft Gynäkologische Onkologie\" (WSG-AGO) EC-Doc is a large trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3 involved lymph nodes (LN).
Epistemonikos ID: 29673052cbf3522c62e1ea924e2da8dfc59317c0
First added on: May 11, 2024